Echec dans le Pseudomonas - NEUTRE vs ACHAT - OC 3,2€ (vs 5,5€)
Après le retrait de GSK du projet dans le C.Diff lors des résultats du T1 16, le groupe a annoncé hier soir l’échec de son candidat vaccin contre le Pseudomonas Aeruginosa en Phase II/III. Suite à cette annonce, nous retirons toutes les ventes anticipées pour ce composé auxquelles nous appliquions initialement une POS de 60%. Ceci nous conduit à abaisser notre objectif de 5,5€ à 3,2€ et à modifier notre recommandation d’ACHAT à NEUTRE dans l’attente d’avoir un peu plus de visibilité sur le renouveau du pipeline à court terme.Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.